JP2024530368A5 - - Google Patents
Info
- Publication number
- JP2024530368A5 JP2024530368A5 JP2023547736A JP2023547736A JP2024530368A5 JP 2024530368 A5 JP2024530368 A5 JP 2024530368A5 JP 2023547736 A JP2023547736 A JP 2023547736A JP 2023547736 A JP2023547736 A JP 2023547736A JP 2024530368 A5 JP2024530368 A5 JP 2024530368A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- solvate
- antibody
- variable region
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025130431A JP2025183203A (ja) | 2020-10-15 | 2025-08-05 | 抗体薬物複合体およびその用途 |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011105383.0A CN114366818B (zh) | 2020-10-15 | 2020-10-15 | 抗体药物偶联物及其应用 |
| PCT/CN2021/124698 WO2022078523A1 (zh) | 2020-10-15 | 2021-10-19 | 抗体药物偶联物及其应用 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025130431A Division JP2025183203A (ja) | 2020-10-15 | 2025-08-05 | 抗体薬物複合体およびその用途 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024530368A JP2024530368A (ja) | 2024-08-20 |
| JP2024530368A5 true JP2024530368A5 (enExample) | 2024-09-25 |
| JP7724866B2 JP7724866B2 (ja) | 2025-08-18 |
Family
ID=81138741
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023547736A Active JP7724866B2 (ja) | 2020-10-15 | 2021-10-19 | 抗体薬物複合体およびその用途 |
| JP2025130431A Pending JP2025183203A (ja) | 2020-10-15 | 2025-08-05 | 抗体薬物複合体およびその用途 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025130431A Pending JP2025183203A (ja) | 2020-10-15 | 2025-08-05 | 抗体薬物複合体およびその用途 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20230381336A1 (enExample) |
| EP (1) | EP4230225A4 (enExample) |
| JP (2) | JP7724866B2 (enExample) |
| KR (1) | KR102921110B1 (enExample) |
| CN (1) | CN114366818B (enExample) |
| AU (1) | AU2021359562A1 (enExample) |
| CA (1) | CA3198667A1 (enExample) |
| CL (1) | CL2023001073A1 (enExample) |
| CO (1) | CO2023005979A2 (enExample) |
| CR (1) | CR20230207A (enExample) |
| IL (1) | IL302122A (enExample) |
| MX (1) | MX2023004236A (enExample) |
| WO (1) | WO2022078523A1 (enExample) |
| ZA (1) | ZA202304381B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3264030A1 (en) * | 2022-08-04 | 2024-02-08 | Memorial Hospital For Cancer And Allied Diseases | Anti-CD24 antibodies and their uses |
| JP2025532659A (ja) * | 2022-09-19 | 2025-10-01 | シャンハイ ミラコーケン インコーポレイティド | Ｅｇｆｒを標的とする抗体薬物複合体による鼻咽頭癌の治療 |
| EP4591887A1 (en) * | 2022-09-22 | 2025-07-30 | Lepu Biopharma Co., Ltd. | Gpc3 antibody-drug conjugate and use thereof |
| WO2025078686A1 (en) | 2023-10-12 | 2025-04-17 | Sotio Biotech A.S. | Combination therapy involving antibody-drug conjugates against claudin18.2 and pd1/pd-l axis inhibitors for treatment of cancer |
| WO2025088105A1 (en) | 2023-10-27 | 2025-05-01 | Keymed Biosciences (Chengdu) Co., Ltd | Cancer treatment with anti-claudin 18.2 adc |
| WO2025086270A1 (en) | 2023-10-27 | 2025-05-01 | Keymed Biosciences (Chengdu) Co., Ltd. | Cancer treatment with anti-claudin 18.2 adc |
| WO2025086268A1 (en) | 2023-10-27 | 2025-05-01 | Keymed Biosciences (Chengdu) Co., Ltd. | Cancer treatment with anti-claudin 18.2 adc |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016165762A1 (en) * | 2015-04-15 | 2016-10-20 | Ganymed Pharmaceuticals Ag | Drug conjugates comprising antibodies against claudin 18.2 |
| CA3044898C (en) * | 2016-11-25 | 2022-04-05 | Mabwell (shanghai) Bioscience Co., Ltd. | Di-substituted maleic amide linker for antibody-drug conjugating and preparation method and use thereof |
| CN109810039B (zh) * | 2017-11-22 | 2021-11-12 | 迈威(上海)生物科技股份有限公司 | 一种用于抗体-药物偶联的双取代马来酰胺类连接子及其制备方法和用途 |
| CN111110862A (zh) * | 2018-11-01 | 2020-05-08 | 上海健信生物医药科技有限公司 | 抗cldn18．2抗体的药物偶联体及其制备方法和用途 |
| WO2019242505A1 (zh) * | 2018-06-17 | 2019-12-26 | 上海健信生物医药科技有限公司 | 靶向cldn18.2的抗体、双特异性抗体、adc和car及其应用 |
| CN109762067B (zh) * | 2019-01-17 | 2020-02-28 | 北京天广实生物技术股份有限公司 | 结合人Claudin 18.2的抗体及其用途 |
| EP3960766A4 (en) * | 2019-04-19 | 2022-12-07 | Keymed Biosciences Co.,Ltd. | ANTI-TUMOR THERAPEUTIC AGENT AND USE THEREOF |
-
2020
- 2020-10-15 CN CN202011105383.0A patent/CN114366818B/zh active Active
-
2021
- 2021-10-19 AU AU2021359562A patent/AU2021359562A1/en active Pending
- 2021-10-19 JP JP2023547736A patent/JP7724866B2/ja active Active
- 2021-10-19 WO PCT/CN2021/124698 patent/WO2022078523A1/zh not_active Ceased
- 2021-10-19 KR KR1020237014724A patent/KR102921110B1/ko active Active
- 2021-10-19 MX MX2023004236A patent/MX2023004236A/es unknown
- 2021-10-19 CR CR20230207A patent/CR20230207A/es unknown
- 2021-10-19 EP EP21879564.9A patent/EP4230225A4/en active Pending
- 2021-10-19 US US18/031,731 patent/US20230381336A1/en active Pending
- 2021-10-19 IL IL302122A patent/IL302122A/en unknown
- 2021-10-19 CA CA3198667A patent/CA3198667A1/en active Pending
-
2023
- 2023-04-13 ZA ZA2023/04381A patent/ZA202304381B/en unknown
- 2023-04-14 CL CL2023001073A patent/CL2023001073A1/es unknown
- 2023-05-10 CO CONC2023/0005979A patent/CO2023005979A2/es unknown
-
2024
- 2024-10-09 US US18/910,550 patent/US20250032633A1/en active Pending
-
2025
- 2025-08-05 JP JP2025130431A patent/JP2025183203A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024530368A5 (enExample) | ||
| JP7386208B2 (ja) | 抗ｆｏｌｒ１免疫抱合体投薬レジメン | |
| TWI851552B (zh) | 磷脂醯肌醇蛋白聚醣(glypican)3抗體及其結合物 | |
| JP2025183203A5 (enExample) | ||
| JP7585230B2 (ja) | バイパラトピックＦＲ－α抗体及びイムノコンジュゲート | |
| Hamblett et al. | Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate | |
| ES2795818T3 (es) | Anticuerpos CD48 y conjugados de los mismos | |
| JP2021102648A (ja) | 抗ｆｏｌｒ１免疫複合体投与計画 | |
| US9107962B2 (en) | Anthracycline-antibody conjugates for cancer therapy | |
| JP2023022328A5 (enExample) | ||
| JP2020510677A (ja) | 抗体−薬物複合体化のための二置換マレインアミドリンカーならびにその調製方法および使用 | |
| CN106999606A (zh) | 抗体药物偶联物 | |
| CN107735093A (zh) | Cd123抗体和其结合物 | |
| JP2015527318A5 (enExample) | ||
| JP2018501781A5 (enExample) | ||
| JP2022547434A (ja) | 標的化デンドリマー複合体 | |
| EP4378958A3 (en) | High-affinity anti-mertk antibodies and uses thereof | |
| JP2022538908A5 (enExample) | ||
| JP2023036874A (ja) | イムノコンジュゲートにおけるメチオニン酸化を防止する方法 | |
| EP4642488A1 (en) | Antibody drug conjugates | |
| US20250049938A1 (en) | Antibody-drug conjugate and use thereof | |
| JPWO2021251459A5 (enExample) | ||
| JP2016540826A5 (enExample) | ||
| WO2020108612A1 (zh) | 一种c-Met ADC在制备治疗c-Met激酶抑制剂耐药的疾病的药物中的用途 | |
| RU2849612C2 (ru) | Конъюгат антитело-препарат и его применение |